DOCSLIB.ORG

Pharmacology of Corticosteroids

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacology of Corticosteroids Editing File Mnemonic File Endocrine Block Pharmacology team 438 Pharmacology of Corticosteroids Objectives: By the end of the lecture , you should know: ● Revise the synthesis of steroids ● Mechanism of action ● Pharmacokinetics of cortisol, pharmacodynamic actions and ● therapeutic uses ● Adverse reaction ● Steroids agonists and antagonists and their therapeutic applications. Color index: Black : Main content Purple: Females’ slides only Red : Important Grey: Extra info or explanation Blue: Males’ slides only Green : Dr. notes Biosynthesis of Adrenal Hormone1 Corticosteroid is present in Mineralocorticoids Glucocorticoids Sex hormones the blood bound to the 1 corticosteroid binding The intracellular receptor is bound globulin (CBG) and enters the Cholesterol to the stabilizing proteins, cell as the free molecule. including heat shock protein 90 ACTH (Hsp90) and several others (X). 2 When the complex binds a 11αOH 11-OH 17,20 lyase Dehydroepiandro Pregnenolone molecule of steroid, the Hsp90 and pregnenolone sterone (DHEA) associated molecules are released. The Steroid – receptor complex enters the nucleus as a dimer, 11αOH 11-OH 17,20 lyase Progesterone Androstenodione binds to the glucocorticoid progesterone response element (GRE) on the 3 11-Deoxy gene, and regulates gene transcription by RNA corticosterone 11-Deoxy cortisol Testosterone The resulting mRNA is edited polymerase2 and associated and exported to the transcription factors. Corticosterone cytoplasm for the production 4 of protein that brings about AT II the final hormone response. - Dihydrotestosterone Aldosterone Cortisol - Estradiol Corticosteroid is present in the blood bound to the corticosteroid binding globulin (CBG) and enters Corticosteroids The intracellular receptor is bound to the the cell as the free molecule. stabilizing proteins, including heat shock Corticosteroids are steroid hormones produced by the adrenal cortex. They consist of two groups: protein 90 (Hsp90) and several others (X). When the complex binds a molecule of They have important The Steroid – receptor complex enters the They have steroid, the Hsp90 and associated molecules effects on nucleus as a dimer, binds to the 3 Glucocorticoids: salt-retaining activity are released. intermediary 2 glucocorticoid response element (GRE) on Cortisol (Hydrocortisone ) which regulate Na & K metabolism, the gene, and regulates gene transcription reabsorption in the catabolism, immune Mineralocorticoids: by RNA polymerase2 and associated collecting tubules of The resulting mRNA is edited and responses, growth & Aldosterone transcription factors. inflammation. the kidney exported to the cytoplasm for the production of protein that brings about the final hormone response. Mechanism of action: Corticosteroid is present in the blood bound to the corticosteroid binding globulin (CBG) 1 and enters the cell as the free molecule. 2 The intracellular receptor is bound to the stabilizing proteins, including heat shock protein 2 90 (Hsp90) and several others (X). When the complex binds a molecule of steroid, the Hsp90 and associated molecules are released. 3 1 The Steroid – receptor complex enters the nucleus as a dimer, binds to the glucocorticoid response 3 element (GRE) on the gene, and regulates gene transcription by RNA polymerase 2 and associated 4 transcription factors. The resulting mRNA is edited and exported to the cytoplasm for the production of protein 4 that brings about the final hormone response. 1: all are derivatives of cholesterol 2: synthetic/pharmaceutical form of cortisol. 3: Are all reactions related to generation and storage of metabolic energy Effects of Glucocorticoids: ● Glucocorticoid stimulate gluconeogenesis, as a result: ○ Blood glucose rises ○ Insulin secretion is stimulated→Lipolysis and lipogenesis are stimulated. With a net increase of Metabolic effects fat deposition in certain areas [e.g. the face (moon facies), shoulder and back (buffalo hump)] ★ These effects occur when the patient is treated with 100 mg (high dose) of hydrocortisone or > for longer than 2 weeks. ● Glucocorticoids cause muscle protein catabolism(↓muscle mass/muscle wasting). ● Lymphoid and connective tissue fat and skin undergo Catabolic effects wasting . ● Catabolic effects on bone lead to osteoporosis ★ In children growth is inhibited1. ● Glucocorticoids inhibit cell mediated immunologic functions, especially dependent on lymphocytes & Immunosuppressive decrease interleukins secretion. effects2 ★ Glucocorticoids do not interfere with the development of normal acquired3 immunity but delay rejection reactions in patients with organ transplants. ● Glucocorticoids have important inhibitory effects on the distribution, function and migration of leukocytes. Anti inflammatory ● Suppressive effect on the inflammatory cytokines & effect2 chemokines. ● These drugs increase neutrophils and decrease lymphocytes, eosinophils, basophils and monocytes. ★ Inhibit phospholipase A24 & Prostaglandins synthesis. ● Renal: Glucocorticoids such as cortisol are required for normal renal excretion of water loads. ● CNS: When given in large doses these drugs may cause Other effects profound behavioral changes (first insomnia & euphoria then depression). ● GIT: Large doses also stimulate gastric acid secretion and decrease resistance5 to ulcer formation. 1: Steroids are contraindicated in children 2: most common therapeutic uses of steroids.. 3: = Adaptive. 4: enzyme responsible for liberation of arachidonic acid (first step in the arachidonic acid pathway) which inhibit the production of all prostanoids and leukotrienes. 5: decrease prostaglandins Natural Overview Cortisol ( hydrocortisone) Glucocorticoids Synthetic E.g Prednisone \ Dexamethasone1 Agonist Antagonist Budesonide \ Beclomethasone Agonist Spironolactone Natural Aldosterone Glucocorticoids Mineralocorticoids Mineralocorticoids Aldosterone Mifepristone Synthetic Flucocortisone (Fludrocortisone) Natural synthetic Glucocorticoids Glucocorticoids Ketoconazole Glucocorticoids Cortisol receptors Prednisone (hydrocortisone) E.g Mifepristone Aminogluthemide Receptor antagonist Prednisolone Mineralocorticoids receptors Metrapone E.g Spironolactone Dexamethasone Antagonist Classification of Corticosteroids Triamcinolone Synthetic E.g Ketoconazole inhibitors Beclomethasone Glucocorticoids Some commonly used naturalBudesonide and synthetic corticosteroids for general use Natural cortisol (hydrocortisone) Synthetic Glucocorticoids ● Cortisol is the major natural glucocorticoid. Activity Activity ● AgentsThe physiologic secretion of cortisol is regulated by adrenocorticotropic (ACTH) & secretion rate ● is the major natural glucocorticoid. Agent varies during the dayAnti-inflammatory (Circadian rhythm). Peaks in the Topical morning and trough (declines)Salt-retaining in midnight. ● The physiologic secretion of cortisol is ● Prednisone and its active Anti-inflammatory Topical Salt-retaining Drugs regulated by adrenocorticotropic metabolite prednisolone Short to medium acting glucocorticoids (ACTH) & secretion rate varies during ● Dexamethasone Short to medium acting glucocorticoids the day (Circadian rhythm). Peaks in ● Budesonide Hydrocortisone the morning and trough (declines) in ● Beclomethasone Hydrocortisone 1 1 1 1 1 1 (cortisol) midnight. (cortisol) Cortisone 0.8 0 0.8 ● Given orally, cortisol is well absorbed Cortisone 0.8 0 0.8 from GIT Prednisone 4 0 0.3 ● Cortisol in the plasma is 95% bound Prednisone 4 0 0.3 to CBG Prednisolone 5 4 0.3 ● It is metabolized by the liver & has ★ Their properties in compared to Prednisolone 5 4 0.3 short duration of action compared cortisol include: Methyl- with the synthetic congeners ○ longer half life Long acting glucocorticoids prednisolone ● It diffuses poorly across normal skin ○ longer duration of action P.K & mucous membranes ○ reduce salt retaining effect Betamethasone 25-40 10 0 Meprednisone ● The cortisol molecule also has a small ○ better penetration of lipid but significant mineralocorticoid barriers for topical activity. Dexamethasone 30 10 0 Long acting glucocorticoids effect. This is an important cause of hypertension in patients with cortisol Mineralocorticoids Betamethasone 25-40 10 0 secreting adrenal tumor or a pituitary ACTH secreting tumor (Cushing’s Fludrocotisone 10 0 250 Dexamethasone 30 10 0 syndrome) Mineralocorticoids 1: long acting. Fludrocortisone 10 0 250 Glucocorticoids Cont... Drugs Natural cortisol (hydrocortisone) Synthetic Glucocorticoids ● Adrenal Disorder: 1. Addison’s disease (chronic adrenocortical insufficiency) 2. Acute adrenal insufficiency associated with life threatening shock, infections or trauma 3. Congenital adrenal hyperplasia (in which synthesis of abnormal forms of corticosteroids are stimulated by ACTH). ● Non- adrenal Disorder: 1. Allergic reactions1 (e.g. bronchial asthma, angioneurotic edema,drug reactions, urticaria, allergic rhinitis) a. Beclomethasone & budesonide have been developed for use in asthma and other condition in which good surface activity on mucous membrane or skin is needed and systemic effects are to be avoided. b. Rapidly penetrate the airway mucosa but have very short half lives after they enter the blood, so that systemic effects and toxicity are greatly reduced. (advantage) Uses 2. Collagen vascular disorder2 (e.g rheumatoid arthritis, systemic lupus erythematosus, giant cell arteritis, polymyositis, mixed connective tissue syndrome) 3. Organ transplants (prevention & treatment of rejection – immunosuppression) 4. GI disorders (e.g inflammatory bowel disease)
Load more

Recommended publications
  • United States Patent 19 11 Patent Number: 5,449,515 Hamilton Et Al
    USOO5449515A United States Patent 19 11 Patent Number: 5,449,515 Hamilton et al. 45 Date of Patent: Sep. 12, 1995 (54). ANTI-INFLAMMATORY COMPOSITIONS WO9005183 5/1990 WIPO : AND METHODS OTHER PUBLICATIONS 75 Inventors: John A. Hamilton, Kew; Prudence H. Schleimer, R. P. et al., "Regulation of Human Basophil Hart, Millswood, both of Australia mediator ... ', J. Immuno., vol. 143, (4), Aug. 15, 1989, 73 Assignee: University of Melbourne, Victoria, pp. 1310-1317. Australia Hart et al., “Augmentation of Glucocorhicoid Action 21 Appl. No.: 858,967 on Human...” Lymphokine Research, vol. 9 (2), 1990, pp. 147-153. 22, PCT Filed: Nov. 21, 1990 Hart, P. H. et al., "Potential antiinflammatory effects of 86 PCT No.: PCT/AU90/00558 IL-4, Proc. Natl. Acad. Sci., vol. 86, pp. 3803-3807, May 1989. S 371 Date: Jul. 14, 1992 Hart, et al., Proc. Natl. AcadSci, vol. 86 pp. 3803-3807, S 102(e) Date: Jul. 14, 1992 May (1989). 87 PCT Pub. No.: WO91/07186 Primary Examiner-Michael G. Wityshyn Assistant Examiner-C. Sayala PCT Pub. Date: May 30, 1991 Attorney, Agent, or Firm-Jan P. Brunelle; Walter H. 30 Foreign Application Priority Data Dreger Nov. 21, 1989 IAU Australia ............................... PJTSO3 57 ABSTRACT 51 Int. CI.'.............................................. A61K 45/05 Therapeutic compositions and methods for the treat 52 U.S.C. .................................... 424/85.2; 530/351 ment of inflammation are disclosed. The compositions 58) Field of Search ........................ 424/85.2; 530/351 comprise at least one anti-inflammatory drug in combi nation with the lymphokine interleukin-4 (IL-4), which 56) References Cited components interact synergistically in the treatmement U.S.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al
    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Contact Dermatitis to Medications and Skin Products
    Clinical Reviews in Allergy & Immunology (2019) 56:41–59 https://doi.org/10.1007/s12016-018-8705-0 Contact Dermatitis to Medications and Skin Products Henry L. Nguyen1 & James A. Yiannias2 Published online: 25 August 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Consumer products and topical medications today contain many allergens that can cause a reaction on the skin known as allergic contact dermatitis. This review looks at various allergens in these products and reports current allergic contact dermatitis incidence and trends in North America, Europe, and Asia. First, medication contact allergy to corticosteroids will be discussed along with its five structural classes (A, B, C, D1, D2) and their steroid test compounds (tixocortol-21-pivalate, triamcinolone acetonide, budesonide, clobetasol-17-propionate, hydrocortisone-17-butyrate). Cross-reactivities between the steroid classes will also be examined. Next, estrogen and testosterone transdermal therapeutic systems, local anesthetic (benzocaine, lidocaine, pramoxine, dyclonine) antihistamines (piperazine, ethanolamine, propylamine, phenothiazine, piperidine, and pyrrolidine), top- ical antibiotics (neomycin, spectinomycin, bacitracin, mupirocin), and sunscreen are evaluated for their potential to cause contact dermatitis and cross-reactivities. Finally, we examine the ingredients in the excipients of these products, such as the formaldehyde releasers (quaternium-15, 2-bromo-2-nitropropane-1,3 diol, diazolidinyl urea, imidazolidinyl urea, DMDM hydantoin), the non- formaldehyde releasers (isothiazolinones, parabens, methyldibromo glutaronitrile, iodopropynyl butylcarbamate, and thimero- sal), fragrance mixes, and Myroxylon pereirae (Balsam of Peru) for contact allergy incidence and prevalence. Furthermore, strategies, recommendations, and two online tools (SkinSAFE and the Contact Allergen Management Program) on how to avoid these allergens in commercial skin care products will be discussed at the end.
    [Show full text]
  • The Following Content Was Supplied by the Authors As Supporting Material and Has Not Been Copy-Edited Or Verified by JBJS
    COPYRIGHT © BY THE JOURNAL OF BONE AND JOINT SURGERY, INCORPORATED GARCIA ET AL. PERIOPERATIVE CORTICOSTEROIDS REDUCE DYSPHAGIA SEVERITY FOLLOWING ANTERIOR CERVICAL SPINAL FUSION. A META- ANALYSIS OF RANDOMIZED CONTROLLED TRIALS http://dx.doi.org/10.2106/JBJS.20.01756 Page 1 The following content was supplied by the authors as supporting material and has not been copy-edited or verified by JBJS. APPENDIX MEDLINE ((exp myelopathy/ or exp radiculopathy/).tw.) and ((exp cervical/ or exp anterior/).ab,ti.) and (((exp discectomy/ or (spinal fusion or arthrodesis or decompression)) or exp corpectomy/).tw.) and ((exp steroids/ or exp glucocorticoids/ or exp corticosteroids/).ab,ti.) and ((exp dysphagia/ or exp dysphonia/ or exp swallow/).ab,ti.) EMBASE ('cervical spine'/exp OR 'neck'/exp OR cervical OR neck) AND ('intervertebral diskectomy'/exp OR 'spinal cord decompression'/exp OR 'intervertebral disk'/exp OR 'intervertebral disk degeneration'/exp OR 'intervertebral disk hernia'/exp OR 'radiculopathy'/exp OR 'cervical myelopathy'/exp OR discectomy OR diskectomy OR decompression OR corpectomy OR radiculopath* OR myelopath* OR radiculomyelopath* OR 'radiculo myelopath*' OR myeloradiculopath* OR 'myelo radiculopath*' OR discopath* OR 'diskitis'/exp OR diskitis OR discitis OR ((disc* OR disk*) AND (degenerat* OR displace* OR hernia*)) OR 'anterior spine fusion'/exp OR fusion OR arthrodesis) AND ('glucocorticoid'/exp OR 'steroid'/exp OR 'corticosteroid'/exp OR 'dexamethasone'/exp OR 'betamethasone'/exp OR 'hydrocortisone'/exp OR 'cortisone'/exp OR
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A High-Pressure Vibrational Spectroscopie Study of Polymorphism in Steroids: Progesterone and Spironolactone
    A High-pressure Vibrational Spectroscopie Study of Polymorphism in Steroids: Progesterone and Spironolactone BY Gisia L. Pisegna A thesis submitted to the Faculty of Graduate Studies and Research of McGill University in partial fulfiilntent of the requirements for the degree of Master of Science Novernber 1999 Departrnent of Chemistry McGill University Montréal, Québec, Canada "~isiaL. Pisegna üibîiothèque nationale du Canada Acquisitions and Acquisitions et BiMiographic Services senrices bibliographiques The author has grantecl a non- L'auteur a accordé une licence non exclusive licence dowing the exclusive permettant à la National Lihuy of Canada to Bibliothèque nationale du Canada de reprodoce, Ioan, distribute or seil reproduire, prêter, distribuer ou copies of this thesis in microform, vendre des copies de cette thèse sous paper or electronic formats. la forme de mic~che/nlm,de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts lkom it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent 'être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. Abstract The effect of high extemal pressures on the vibrational (IR and Raman) spectra of the polymorphs of progestemne and spironolactone has been examined. The high pressures were achieved with the aid of a diamond-anvil ce11 between ambient pressure and 50 kbar (-50,000 atm). The pressure dependences of selected vibrational modes were obtained. Wavenumber vs. pressure plots were used to determine the dv/dp values.
    [Show full text]
  • WO 2014/134394 Al 4 September 2014 (04.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134394 Al 4 September 2014 (04.09.2014) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 9/107 (2006.01) A61K 31/573 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 14/0 19248 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 28 February 2014 (28.02.2014) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/770,562 28 February 2013 (28.02.2013) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: PRECISION DERMATOLOGY, INC. UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, [US/US]; 900 Highland Corporate Drive, Suite 203, Cum TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, berland, RI 02864 (US).
    [Show full text]
  • Using F-NMR and H-NMR for Analysis of Glucocorticosteroids in Creams
    KTH Royal Institute of Technology School of Chemical Engineering Degree project, in KD203X, second level, 2010 Using 19F-NMR and 1H-NMR for Analysis of Glucocorticosteroids in Creams and Ointments - Method Development for Screening, Quantification and Discrimination Angelica Lehnström Supervisors Monica Johansson, Medical Products Agency Ian McEwen, Medical Products Agency Examiner István Furó, Royal Institute of Technology Abstract Topical treatment containing undeclared corticosteroids and illegal topical treatment with corticosteroid content have been seen on the Swedish market. In creams and ointments corticosteroids in the category of glucocorticosteroids are used to reduce inflammatory reactions and itchiness in the skin. If the inflammation is due to bacterial infection or fungus, complementary treatment is necessary. Side effects of corticosteroids are skin reactions and if used in excess suppression of the adrenal gland function. Therefore the Swedish Medical Products Agency has published related warnings to make the public aware. There are many similar structures of corticosteroids where the anti-inflammatory effect is depending on substitutions on the corticosteroid molecular skeleton. In legal creams and ointments they can be found at concentrations of 0.025 - 1.0 %, where corticosteroids with fluorine substitutions usually are found at concentrations up to 0.1 % due to increased potency. At the Medical Products Agency 19F-NMR and 1H-NMR have been used to detect and quantify corticosteroid content in creams and ointments. Nuclear Magnetic Resonance, NMR, is an analytical technique which is quite sensitive and can have a relative short experimental time. The low concentration of corticosteroids makes the signals detected in NMR small and in 1H-NMR the signals are often overlapped by signals from the matrix.
    [Show full text]
  • Wo 2009/063493 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 22 May 2009 (22.05.2009) PCT WO 2009/063493 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/58 (2006.01) A61K 31/575 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, (21) International Application Number: CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, PCT/IN2008/000577 EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (22) International Filing Date: LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, 8 September 2008 (08.09.2008) MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, (25) Filing Language: English RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1725/MUM/2007 kind of regional protection available): ARIPO (BW, GH, 10 September 2007 (10.09.2007) IN GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): GLEN- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), MARK PHARMACEUTICALS LIMITED [IN/IN]; European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, Glenmark house, HDO-Corporate Bldg, Wing-A, B.D FR, GB, GR, HR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, Sawant Marg, Chakala, Andheri (East), Maharashtra (IN).
    [Show full text]
  • Nonspecific Anti-Inflammatory Agents Some Notes on Their Practical Application
    OFFICIAL JOURNAL OF THE CALIFORNIA MEDICAL ASSOCIATION © 1964, by the California Medical Association Volume 100 MARCH 1964 Number 3 Nonspecific Anti-Inflammatory Agents Some Notes on Their Practical Application. Especially in Rheumatic Disorders EDWARD W. BOLAND, M.D., Los Angeles * A number of acute and chronic inflammatory acute rheumatic fever. Steroid therapy should be disorders are amenable to varying degrees of reserved for resistant cases and for those with therapeutic control with the administration of significant carditis. Salicylates are mainstays for nonspecific anti-inflammatory drugs. An evalua- pain relief in rheumatoid arthritis, but with the tion of these suppressive agents in the field of analgesic doses usually employed their anti- rheumatic diseases and practical suggestions re- inflammatory action is slight. garding their administration are presented. Phenylbutazone is a highly useful anti- Eight synthetically modified corticosteroid inflammatory agent, especially in management compounds are available commercially. Each of of acute gouty arthritis and ankylosing (rheu- them exhibits qualitative differences in one or matoid) spondylitis; its metabolite, oxyphenyl- several physiologic actions, each has certain ad- butazone, does not exhibit clear-cut advantages. vantages and disadvantages in therapy, and each Colchicine specifically suppresses acute gouty shares the major deterrent features of cortico- desacetylcolchicine and steroids. Prednisone, prednisolone, methylpred- arthritis. Its analogues, nisolone, fluprednisolone and paramethasone desacetylthiocolchicine, produce fewer unpleas- have similar therapeutic indices, and there is ant gastrointestinal symptoms, but may promote little choice between them for the usual rheu- agranulocytosis and alopecia. matoid patient requiring steroid therapy. Con- A number of indole preparations with anti- versely, the therapeutic indices of dexametha- inflammatory activity have been tested clinically.
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]